Vytrus Biotech (XMAD:VYT) Current Deferred Taxes Liabilities: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:VYT Vytrus Biotech SA XMAD:VYT
69 GF Score
Price €16.95
GF Value €5.71
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Vytrus Biotech Current Deferred Taxes Liabilities?

Vytrus Biotech XMAD:VYT 69 Current Deferred Taxes Liabilities is €0.00 Mil as of Dec. 2025. GuruFocus rates XMAD:VYT with a GF Score™ of 69/100 and a GF Value™ of €5.71 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Vytrus Biotech's current deferred tax liabilities for the quarter that ended in Dec. 2025 was €0.00 Mil.

Vytrus Biotech Current Deferred Taxes Liabilities Related Terms

Vytrus Biotech Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Vytrus Biotech's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vytrus Biotech Current Deferred Taxes Liabilities Chart

Vytrus Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Vytrus Biotech Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XMAD:VYT
69GF Score
Vytrus Biotech SA XMAD:VYT
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of €0.00 Mil mean?
Vytrus Biotech (XMAD:VYT) has a Current Deferred Taxes Liabilities of €0.00 Mil as of Dec. 2025. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Vytrus Biotech and its competitors.
Is Vytrus Biotech's Current Deferred Taxes Liabilities too high?
Vytrus Biotech's current Current Deferred Taxes Liabilities is €0.00 Mil. Overall, Vytrus Biotech has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's Current Deferred Taxes Liabilities compare to VRTX and REGN?
Vytrus Biotech's Current Deferred Taxes Liabilities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Biotechnology company?
A good Current Deferred Taxes Liabilities depends on the Biotechnology industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Vytrus Biotech and its competitors. Vytrus Biotech's current Current Deferred Taxes Liabilities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.71, compared to a current price of €16.95 — trading 196.8% above its estimated fair value. The current Current Deferred Taxes Liabilities is €0.00 Mil. Vytrus Biotech's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current Current Deferred Taxes Liabilities is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?

Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued. The current stock price of €16.95 is trading 196.8% above its estimated GF Value™ of €5.71. GuruFocus considers Vytrus Biotech to be Significantly Overvalued.

Key valuation signals for XMAD:VYT:

  • Current Deferred Taxes Liabilities: €0.00 Mil
  • GF Value™: €5.71 vs. price of €16.95 (196.8% above fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vytrus Biotech Business Description

Other Exchanges V5P:Germany
Address Sant Gaieta 121, 2nd Floor, Terrassa, Barcelona, ESP, 08221
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
69GF Score

Get the complete analysis for XMAD:VYT

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.95
Price
€5.71
GF Value